此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Mosunetuzumab 和 Zanubrutinib 用于治疗复发/难治性边缘区淋巴瘤患者的 2 期试验

2026年9月30日 更新者:M.D. Anderson Cancer Center

To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.

研究概览

地位

招聘中

条件

详细说明

Primary Objectives:

To determine the safety and efficacy of mosunetuzumab in combination with zanubrutinib as determined by best complete response (CR) rate of combination treatment for patients with relapsed or refractory marginal zone lymphoma (MZL).

Secondary Objectives:

To determine best overall response rate (ORR), duration of response (DOR), time to next treatment, progression-free survival (PFS), overall survival (OS), and evaluation of tolerability of mosunetuzumab and zanubrutinib as treatment for patients with relapsed/refractory MZL.

Exploratory Objective:

To determine the impact of total metabolic tumor volume to ORR, CR rate and survival outcomes

To determine the biomarkers that correlates with response and mechanisms of resistance to mosunetuzumab and zanubrutinib in relapsed/refractory MZL.

To determine the surrogate endpoint for future trials in MZL.

研究类型

介入性

注册 (估计的)

36

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • MD Anderson Cancer Center
        • 接触:
        • 首席研究员:
          • Dai Chihara, MD,PHD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Patients must meet the following criteria for study entry:

  1. Histologically diagnosed marginal zone lymphoma (any subtypes)

    o Low grade or indolent B-cell lymphoma unclassifiable is also eligible

  2. Have received at least 1 prior treatment including CD20 monoclonal antibody

  3. Patients have relapsed or refractory disease to their most recent regimen

  4. Stage II, III or IV disease

  5. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of mosunetuzumab and zanubrutinib combination in patients <18 years of age, children are excluded from this study.

  6. Performance status ≤2 on the ECOG scale (≤3 if due to lymphoma)

  7. Requiring systemic therapy assessed by investigator based on tumor size, symptoms and/or GELF criteria

    • A nodal or extranodal (except spleen) mass > 7 cm in its greater diameter

    • At least 3 nodal or extranodal sites ≥ 3 cm in diameter

    • Presence of at least one B symptom

    • Fever (>38 C), night sweats, weight loss > 10% in the past 6 months

    • Symptomatic splenomegaly (or size >13cm)

    • Impending organ compression or involvement (ureteral, orbital, gastrointestinal)

    • Any of the following cytopenias due to bone marrow involvement of lymphoma

      • Hemoglobin ≤ 10 g/dL
      • Platelets ≤ 100 x 109/L
      • Absolute neutrophil count (ANC) < 1.5x109/L
    • Pleural effusion or ascites

    • LDH > ULN or β2 microglobulin > ULN

  8. Bi-dimensionally measurable disease, with at least one nodal lesion ≥ 1.5 cm or one extra-nodal lesion > 1 cm in longest diameter by CT, PET/CT, and/or MRI

    • Subjects with splenic MZL who do not meet the radiographically measurable disease criteria are eligible for participation if spleen is enlarged over 16 cm and MZL is histologically confirmed by bone marrow biopsy or peripheral blood flow cytometry
    • Subjects with EMZL such as skin of conjunctival EMZL who do not meet the radiographically measurable disease criteria are eligible for participation if at least one of the skin lesions is histologically confirmed as MZL and measures ≥1.5 cm in diameter
  9. Patients must have adequate organ and marrow function as defined below:

    • Total bilirubin ≤ 1.5 institutional ULN, unless consistent with Gilbert's (ratio between total and direct bilirubin > 5)

    • AST (SGOT) and ALT (SGPT) ≤ 3 x institutional ULN

    • Alkaline phosphatase < 2.5 ULN

    • Creatinine clearance ≥ 40 ml/min calculated by modified Cockcroft-Gault formula

    • Blood counts below if without lymphoma cause for cytopenia

    • Hemoglobin ≥ 8 g/dL

    • Platelets ≥ 75 x 109/L

    • Absolute neutrophil count (ANC) ≥ 1.0x109/L

    • Blood counts below if cytopenia are due to lymphoma (such as bone marrow involvement or splenomegaly)

      • Hemoglobin ≥ 6 g/dL (no transfusion within 7 days prior to treatment)
      • Platelets ≥ 50 x 109/L
      • Absolute neutrophil count (ANC) ≥ 0.5x109/L

Exclusion Criteria:

Subjects will be ineligible for this study if they meet any of following criteria:

  1. Known active central nervous system lymphoma or leptomeningeal disease.

  2. Treatment with any chemotherapeutic agent, or treatment with any other anti-lymphoma agent (investigational or otherwise) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to first investigational agent administration.

  3. Any prior history of other malignancy besides B-NHL, unless the patient has been free of disease for ≥ 1 year and felt to be at low risk for recurrence by the treating physician, except:

    • Adequately treated localized skin cancer without evidence of disease.
    • Adequately treated or monitored low risk localized prostate cancer.
    • Adequately treated localized breast cancer without evidence of disease.
    • Adequately treated cervical carcinoma in situ without evidence of disease.
  4. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of lenalidomide capsules, or put the study outcomes at undue risk.

  5. Uncontrolled human immunodeficiency virus (HIV), or active Hepatitis C Virus, or active Hepatitis B Virus infection, or any uncontrolled active significant infection, including suspected or confirmed JC virus infection and SARS-CoV2.

  6. Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HBsAg) positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded. Subjects with a history of Hepatitis C who received antiviral treatment are eligible as long as PCR is negative.

  7. History of immunodeficiency (with the exception of hypogammaglobulinemia) or concurrent systemic immunosuppressant therapy (e.g., cyclosporine, tacrolimus, etc., or chronic administration glucocorticoid equivalent of >10mg/day of prednisone) within 28 days of the first dose of study drug with exception of steroid used for IV contrast allergy. In addition, use of inhaled, topical, intranasal corticosteroids or local steroid injection (eg, intra- articular injection) is permitted.

  8. Use of strong/moderate inhibitors within 7 days or 5 half-lives prior to the first dose of zanubrutinib; usage of strong/moderate CYP3A inducers within 14 days prior to the first dose of zanubrutinib.

  9. Requiring ongoing therapy with strong or moderate CYP3A inducers.

  10. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study.

  11. Significant screening electrocardiogram (ECG) abnormalities including 2nd degree atrioventricular (AV) block, type II AV block, or 3rd degree block.

  12. Active bleeding or known bleeding diathesis (e.g., von Willebrand's disease) or hemophilia.

  13. History of stroke or intracranial hemorrhage within 6 months prior to study entry.

  14. Lactating or pregnant subjects.

  15. Administration of any investigational agent within 28 days of first dose of study drug.

  16. Patients who have undergone major surgery within 28 days or minor surgery within 3 days of first dose of study drug.

  17. Patients taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to < 10 mg/day prednisone (over these 4 weeks) with the exception of pre-study steroid treatment with prednisone up to 100mg x 5 days which is allowed to improve symptoms and treatment tolerance.

  18. Known or suspected chronic active Epstein-Barr virus (CAEBV) infection

  19. Administration of a live, attenuated vaccine within 4 weeks before first mosunetuzumab administration or anticipation that such a live, attenuated vaccine will be required during the study.

  20. Prior solid organ transplantation

  21. Prior allogeneic stem cell transplant (autologous stem cell transplants are allowed if conducted at least 100 days prior to C1D1.)

  22. Contraindication to tocilizumab

  23. Patients who have difficulty with or are unable to swallow oral medication, or have disease significantly affecting gastrointestinal function that would limit absorption of oral medication.

  24. Patients who have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.

  25. Patients who have a history of (non-infectious) autoimmune pneumonitis that required steroids or has current autoimmune pneumonitis.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:使用 Mosunetuzumab + Zanubrutinib 治疗

Given by IV

其他名称:
  • RO7030816

Given by IV

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and Adverse Events (AEs)
大体时间:Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Through study completion; an average of 1 year.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Dai Chihara, MD,PHD、M.D. Anderson Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年12月11日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2024年8月19日

首先提交符合 QC 标准的

2024年8月19日

首次发布 (实际的)

2024年8月20日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2024-0243
  • NCI-2024-06965 (其他标识符:NCI-CTRP Clinical Trial Registry)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅